explore -WSS

explore

author：fashion 2025-09-28 23:30:45 - browse：631

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Grail spinoff by Illumina should end disastrous merger attempt

WSS

Artificial intelligence use in health care faces greater scrutiny in 2024

STAT Boddities: What happens to the brain when we get scared?

STAT Boddities: What happens to the brain when we get scared?

Can sheer will power keep patients alive in their dying hours?

Hospitals owned by private equity see complications spike 25%

Artificial intelligence use in health care faces greater scrutiny in 2024

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare drug price negotiation hasn't dried up venture capital

As demand for Covid shots wanes, Moderna seeks its next success

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

At least 13 dead in Texas as scorching temps continue

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Psychedelics group wrestles with new pharma identity

CRISPR gene editing developments we’re watching in 2024

Psychedelics group wrestles with new pharma identity

Editas, Vertex strike deal on CRISPR

focus

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Abbott's new heart device gets FDA advisory panel nod

HCA sued by state AG for quality issues at Mission Health

Too many hospitalized Covid

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Why don't Americans have at

hotspot

hotspot

hotspot

Wikipedia